Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2012

View Archived Issues

Researchers present new mGlu2 receptor modulators

Medivir and Janssen team up to develop new agents for hepatitis

Nektar Therapeutics designs novel polymer-G-CSF conjugates

New fatty acid synthase inhibitors patented by GlaxoSmithKline

Scientists at Callidus Biopharma patent new proteins for lysosomal storage disorders

MABEL dose set for NKG2-A-directed monoclonal antibody

ORCA Therapeutics' lead product set to enter clinic

Canadian company discloses novel calcium channel blockers

New thrombin inhibitors generated by Chinese team

Beta Pharma synthesizes new glucokinase activators

New TYK2 inhibitors designed at Cellzome

Fluorinov Pharma obtains funding to support development of FV-162

MMRF awards funding to Modulation Therapeutics for MTI-101

Clinical and preclinical results on tofogliflozin presented at ADA meeting

Palau Pharma sells histamine H4 receptor antagonist

Clinical trials reveal efficacy of albiglutide in treating diabetes

Cinacalcet trial does not meet primary endpoint

MicroBiopharm Japan and Eisai establish collaboration

Sanofi seeks approval for lixisenatide in Japan

Novel results disclosed on GLP-1 receptor agonist ZYOG-1

Canadian government to fund phase II study of lead Edge Therapeutics product

FDA approves Roche antibody for use in combination cancer therapy

Cancer Research UK opens phase Ib/IIa trial of AstraZeneca drug

Approval sought for topical spray against premature ejaculation

Dosing begins in phase III palifosfamide study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...